Viatris | VTRS - Ebit

Stock Price
16.48
Daily Change
-0.78 -4.52%
Monthly
17.63%
Yearly
86.43%
Q2 Forecast
16.81

Viatris reported $-20.2M in EBIT for its fiscal quarter ending in March of 2026.





Ebit Change Date
Celltrion KRW 12.08B 288.96B Dec/2025
Cspc Pharmaceutical CNY 206.26M 1.02B Dec/2025
Deva Holding AS TRY 820.88M 192.13M Sep/2023
Dianthus Therapeutics USD -69.54M 29.25M Dec/2025
Divis Laboratories Ltd INR 7.72B 30M Dec/2025
Kangmei Pharma CNY -26.7M 43.13M Sep/2025
Knight Therapeutics CAD 6.21M 3.27M Dec/2025
Laboratorios Farma EUR 135.05M 49.84M Dec/2023
Malin Corporation EUR -1.1M 300K Dec/2024
Medical Developments International AUD -36K 12.96M Dec/2025
Neuren Pharmaceuticals AUD 17.01M 154.09M Dec/2025
Organigram Holdings CAD -20.13M 7.92M Dec/2025
Ovoca Bio EUR -1.16M 4.48M Jun/2025
Pharma Mar EUR 622K 42.99M Mar/2026
Qiagen NV USD 121.88M 19.18M Dec/2025
Sartorius EUR 160.7M 94.1M Mar/2026
Sino Biopharmaceutical CNY 5.18B 3.32B Jun/2025
Tilray USD -20.01M 9.34M Sep/2025
Viatris USD -20.2M 137.3M Mar/2026
Zealand Pharma A/S -707.05M 245.73M Dec/2025
Zz Pientze Pharmaceu CNY 837.81M 336.48M Mar/2026